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Usage of supplements has increased dramatically this last decade. From herbs 
to vitamins and mineral, consumers are interested in improving health, self-
treatment and preventing diseases. Often using information from the internet to 
self-prescribe, many consumers believe that natural products are safe, while many 
others avoid using these products because of the lack of an approval process by 
health officials in many countries. Herbs and other supplements including proteins, 
vitamins and minerals provide significant benefits to health. The lack of guidance 
from health professionals however can be problematic. When combined with drugs 
and disease, herbs can interact and cause side effects. Some of the steps to evaluate 
the safe use of supplements is to know their mechanism of action, clinical effect, 
and consumers’ medical history. For example, an herb that induces liver enzymes 
will reduce the effect of a drug that is metabolized by these same enzymes. This can 
be life threating if the patient depends on this drug for normal function. Based on 
drug-herb interaction experience and literature review, this book chapter provides 
insights into safe use of echinacea, licorice, turmeric, and black seed in patients 
with heart disease, diabetes, and COVID-19.
Keywords: herbs, supplements, drug-herb interaction, safety, COVID-19,  
heart disease, diabetes
1. Introduction
Dietary supplements are defined in the United States as products that contain 
one or more dietary ingredient such as vitamins, minerals, herbs, botanicals, 
and amino acids and are intended to supplement the diet [1]. In other countries 
dietary supplements are named differently including natural health products, 
complementary medicines, food supplements, and others [2]. Nonetheless, “dietary 
supplements” is a general term for products that mostly contain herbs, botanicals, 
proteins, and/or vitamins and minerals that are used with the intention to promote 
health. Despite the legal framework, dietary ingredients are often used and recom-
mended for treating or preventing diseases. In this chapter, “dietary supplements” 
will be used as a general term to encompass several dietary ingredients.
Usage of dietary supplements has increased this last two decades [2]. From 
herbs, proteins, to vitamins and minerals, consumers are interested in self-
treatment and preventing diseases [3]. Often using information from the internet 
to self-prescribe, many consumers believe that natural products are safe, while 
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many others avoid using these products because of the lack of an approval process 
by health officials in many countries. Many dietary supplements provide significant 
benefits to health [4]. However, the lack of guidance from health professionals can 
be problematic.
Dietary supplements are likely safe when used as prescribed [4, 5]. But, when 
combined with drugs and disease, these products can interact and cause side effects 
[6, 7]. Some of the steps to evaluate the safe use of dietary ingredients is to know 
their mechanism of action, clinical effect, and consumers’ medical history. For 
example, an ingredient that induces liver enzymes will reduce the effect of a drug 
that is metabolized by these same enzymes. This can be life threating if the patient 
depends on this drug for normal function.
Due to the benefits that several of these dietary ingredients provide, it is impor-
tant to evaluate their safety for wide spread recommendation. Particularly due to 
times of pandemic such as the coronavirus disease 2019 (COVID-19) [8], ways to 
prevent disease severity and to be used as adjunct treatments are needed. Several 
dietary ingredients have been reported to be effective against COVID-19 in review 
articles. For this book chapter, 30 review articles and meta-analysis were evalu-
ated for the selection of the dietary ingredients herein discussed. The selection 
criterium was based on the number of articles that cited the ingredients as being 
effective as well as the commonality and accessibility of the ingredients across the 
globe. Vitamins and minerals were excluded due to their safety being extensively 
researched. Because COVID-19 severity is worse among patients with diabetes and 
cardiovascular disease, the safety use of these ingredients in the context of these 
comorbidities are presented here.
2. Comorbidities and their drug treatments
2.1 COVID-19
COVID-19 is a respiratory infection caused by the virus named “severe acute 
respiratory syndrome coronavirus 2” (SARS-CoV-2) [8]. COVID-19 is a novel 
disease officially declared as a pandemic on March 11th, 2020 [9, 10]. SARS-CoV-2 
has infected 98.2 million people worldwide and caused 2.1 million deaths as of 
January 24th, 2021 [11]. COVID-19 is characterized by dry cough, fever, and fatigue 
symptoms in adults while in children rhinorrhea, abdominal pain, and diarrhea are 
also present [10]. SARS-CoV-2 binds directly to angiotensin converting enzyme 2 
(ACE2) for subsequent entry into cells [10, 12]. Infected cells respond to the virus 
by generating pro-inflammatory cytokines and chemokines that sometimes lead 
to a cytokine storm which aggravates the disease [10, 12, 13]. Those with certain 
underlying health conditions such as respiratory disease, cardiovascular disease, 
and diabetes as well as older individuals seem to be at a higher risk for develop-
ing severe complications from the infection [14, 15]. Because SARS-CoV-2 has 
approximately 80% genomic homology with SARS-CoV-1, the virus that caused the 
2002–2003 epidemic, many research studies have proposed the use of treatments 
that were effective against SARS-CoV-1 [9]. Current treatments for COVID-19 used 
in the clinics are ACE2 inhibitors, corticosteroids, chloroquine, anti-inflammatory 
tocilizumab, comostat, protease inhibitors (lopivavir and ritonavir), and RNA 
polymerase inhibitors (remdesivir, favipiravir) [16]. Some of the established 
protocols are: no treatment for mild cases besides acetaminophen for fever; 
hydroxychloroquine + azithromycin for moderate cases; tocilizumab or sarilumab 
for worsening respiratory function; and remdesivir, convalescent plasma, corti-
costeroids for respiratory failure. NSAIDs such as ibuprofen are not recommended 
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due to potential increase in ACE2 expression [17]. Lastly, it has been suggested that 
reduction in cholesterol decreases viral mRNA [18]. Thus, treatments that reduce 
cholesterol in addition to antivirals, anti-inflammatories, and respiratory support 
should be beneficial in managing COVID-19.
2.2 Heart disease and diabetes
As noted above, patients with heart disease and diabetes are more likely to 
develop severe COVID-19. Thus, many of these patients will be given medications for 
COVID-19 on top of the current heart/diabetes medications they take. For example, 
patients continue to take ACE inhibitors or angiotensin II receptor blockers (ARBs) 
during COVID-19 infection [17]. Furthermore, these are the patients more likely 
to benefit from dietary ingredients that assist in preventing or treating COVID-19. 
Due to multiple treatments at once, the likelihood of drug–drug and drug-herb 
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Meglitinides, repaglinide Metabolized by CYP3A4 Minimal renal excretion [21]
Metformin Minimal metabolism ~90% renal excretion [22]
Glitazones, pioglitazone Metabolized by CYP2C8 ~15–30% renal excretion [21]
Table 1. 
Metabolism and excretion of some common medications used in COVID-19, heart disease and diabetes.
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interaction in these patients is high. Drug treatments for heart disease include several 
types: anticoagulants, antiplatelets, ACE inhibitors, ARBs, beta blockers, calcium 
channel blockers, cholesterol lowering, diuretics, and vasodilators [19]. For diabe-
tes main medication classes include sulfonylureas, meglitinides, metformin, and 
glitazones [20]. The metabolism of some commonly prescribed of these medications 
are listed in Table 1. As noted, the most common cytochrome P450 enzyme involved 
in the metabolism of these drugs are CYP3A4, followed by CYP2C9, 2D6, and 2C8 
[21–25]. Approximately half of them are primarily excreted via the kidneys.
3. Echinacea spp. (echinacea) – Antiviral and immune support
3.1 Echinacea in COVID-19
Echinacea has antiviral and immunomodulatory effects that seems to be promis-
ing against COVID-19 [13, 26]. Several studies have investigated the benefits of 
echinacea in treating and preventing respiratory tract infections such as the com-
mon cold, but not for other health purposes [27]. No studies have yet been com-
pleted on echinacea and COVID-19 [28]. A meta-analysis including 17 clinical trials 
found that echinacea is safe and effective in preventing or treating viral infections. 
In a separate analysis including 12 clinical trials, echinacea showed to decrease or 
not change pro-inflammatory cytokines associated with cytokine storm (IL-6, 
IL-1β, and TNF-α) and increase or not change anti-inflammatory or immune-
stimulatory cytokines (IL-10, IL-2, IL-8, IL-3, and IFN-γ). These effects are benefi-
cial during infections since immune stimulatory and anti-inflammatory effects are 
needed but pro-inflammatory cytokines can aggravate the disease. Adverse events 
were mild with the most common reported being insomnia, gastrointestinal, and 
anxiety. One case of serious erythema was reported. Most studies included healthy 
participants and echinacea dose and method of extraction were quite variable 
 making it difficult to evaluate safety in patients with comorbidities [28].
3.2 Echinacea in diabetes
Not many studies have investigated the effects of echinacea in diabetes. In 
Wistar rats, 33 days of echinacea root extract showed hypoglycemic activity similar 
to glibenclamide. No safety parameters were investigated [29]. Echinacea purpurea 
flower extract and caffeic acid derivatives inhibited α-amylase, α-glucosidase, and 
ACE activities in a concentration-dependent manner [30].
3.3 Echinacea in heart disease
Almost no studies have evaluated the effects of echinacea on heart conditions 
such as hypertension and hypercholesterolemia. In one study with 374 elderly, 349 
reported to use over-the-counter drugs and 43 reported to use herbal medicine. 
Echinacea was the most common herbal therapy used while aspirin, acetaminophen, 
laxatives, antiacids, and vitamins were the most common over-the-counter drugs 
[31]. This single study suggests the potential for interaction of echinacea with drugs.
3.4 Echinacea toxicity
In a review article, echinacea was considered to have a high or medium evidence 
for efficacy and safety [32]. Debatable concern of hepatotoxicity with echinacea 
when used for more than 8 weeks has been raised [6]. On the other hand, echinacea 
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has shown hepatic and renal protection against toxins in rats with no effect by itself 
on liver and kidney parameters including AST, ALT, ALP, blood urea nitrogen and 
creatinine [33]. No toxicity was found in rats and mice after oral or intravenous 
injection of Echinacea purpurea at high doses. No evidence of mutagenicity in vitro 
and in mice or carcinogenicity in hamster embryo cells [34]. Echinacea is contrain-
dicated in patients with autoimmune disease. Little evidence to evaluate the effect 
of echinacea in renal impairment [35].
3.5 Echinacea pharmacokinetics
In vivo pharmacokinetics in 12 healthy men and women, Echinacea purpurea 
root inhibited CYP1A2 and induced CYP3A enzymes [36]. In another similar study 
with 13 healthy adults, Echinacea purpurea induced CYP3A enzymes but did not 
change the pharmacokinetics of ritonavir. Ritonavir is an inhibitor of CYP3A thus 
likely counteracted the induction caused by echinacea. No effect on p-glycoprotein 
was found [37]. In an in vitro study, Echinacea purpurea showed mixed effects on 
CYP3A4 and moderate inhibition of CYP2C9 [38]. A review article found echinacea 
to have high likelihood of drug-herb interaction [39].
3.6 Echinacea safety summary
Echinacea is likely safe when taken short-term, up to 8 weeks, in healthy adults. 
Unknown safety in patients with diabetes or heart disease. Caution should be taken 
when combining with medications metabolized by CYP3A, 1A2, and 2C9 enzymes.
4. Glycyrrhiza sp. root (licorice) – Antiviral and respiratory support
4.1 Licorice in COVID-19
Licorice root is used as a flavoring agent in food in many countries. In the United 
States, anise oil is often used for this purpose. Licorice is promoted as a dietary sup-
plement for digestion, cough, infections, and others [40]. Frequently recommended 
by herbalists, licorice has recently shown to be the herb most frequently used for 
COVID-19 treatment [41, 42]. Several review articles have discussed the potential 
effectiveness of licorice in treating COVID-19 for its antiviral, anti-inflammatory, 
spasmolytic, and expectorant effects [9, 10, 12–14]. Some in vitro studies showed 
that the active component glycyrrhizin inhibits the replication of SARS-coronavirus 
(SARS-CoV) [43, 44]. Other in vitro studies showed that glycyrrhizin may prevent 
SARS-CoV-2 entry by binding to ACE2 receptors and other protein targets [45, 46]. 
Clinical trials of licorice use during COVID-19 are ongoing. Daily doses range from 
250 mg 25% extract (62.5 mg glycyrrhizin) for 10 days to 2.28 g 3% extract (70 mg 
glycyrrhizin) for 7 days [47, 48].
4.2 Licorice in diabetes
Not many studies have investigated the effects of licorice in diabetes. In a clinical 
trial with 58 overweight and obese but otherwise healthy volunteers, 1.5 g licorice 
extract (<0.01% glycyrrhizin) for 8 weeks decreased insulin and HOMA-IR without 
side effects [49]. In cell cultures, de-glycyrrhizinated or regular licorice showed 
to be a potential therapeutic target in diabetic nephropathy [50]. In diabetic mice, 
licorice hydrophobic flavonoids demonstrated abdominal fat-lowering and hypo-
glycemic effects [51].
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4.3 Licorice in heart disease
Cases of hypokalemia and hypertension have been reported after daily inges-
tion of licorice tea or after short-term high dose [52–54]. In one case patient was 
combining licorice with the glucocorticoid medication fludrocortisone [55]. The 
active components of licorice, glycyrrhizinates, inhibit the enzyme responsible for 
inactivating cortisol and bind to mineralocorticoid receptors resulting in reversible 
hyper-mineralocorticoid effects [56]. A meta-analysis with 18 clinical trials found 
that chronic daily intake of 100 mg glycyrrhizin increases systolic and diastolic blood 
pressure [57]. In another meta-analysis including 26 clinical trials and 985 subjects, 
mainly healthy and overweight but some with hypercholesterolemia, found licorice 
to reduce body weight and BMI but increase diastolic blood pressure. Licorice was 
given as licorice flavonoid oil with a dose range of 300 mg to 1.8 g/day for 2–16 weeks 
[58]. In a dose–response relationship investigation in healthy men and women, lico-
rice root with 108 or 217 mg of glycyrrhizin per day for 4 weeks caused no adverse 
events. However, licorice with 380 and 814 mg glycyrrhizin caused headache, arterial 
hypertension, hyperkalemia, and peripheral edema. One individual had a family his-
tory of hypertension [59]. Lastly, a similar study compared adverse events in patients 
with hypertension versus normotensive individuals during 100 g licorice containing 
150 mg glycyrrhetinic acid per day for 4 weeks. Systolic and diastolic blood pressure 
were slightly increased in normotensive (3.5 and 3.6 mmHg) but significantly greater 
increase in hypertensive patients (15.3 and 9.3 mmHg). Increase in urinary cortisol 
correlated with the rise in blood pressure [60]. These data suggest that glycyrrhizin 
at dose >200 mg/day short-term and > 100 mg/day long-term in patients or healthy 
individuals can cause reversible hyperkalemia and hypertension.
4.4 Licorice toxicity
Despite licorice being a substance generally recognized as safe (GRAS) in 
the United States [61] and regarded as having a high safety profile because it is 
consumed as food [32], licorice can cause hypertension and hypokalemia in a 
dose-dependent manner [57]. However, safe dose will vary depending on licorice’s 
composition and the underlying medical conditions. Those with hypertension, heart 
or kidney disease are more sensitive to licorice toxicity [40]. In a study involving 360 
subjects, no clinically significant change in renal function (potassium, blood urea 
nitrogen, and creatinine levels) were found in 98.3% of the subjects after ~19 days 
of ~8 g licorice per day taken as dietary supplements that contained other ingre-
dients. The remaining 1.7% of subjects developed hyperkalemia [62]. In a safety 
and toxicity study with 39 healthy female and male volunteers aged 19–40 years 
old, glycyrrhizic acid was administered at 1, 2, and 4 mg/kg body weight daily for 
8 weeks. A no-effect level of 2 mg/kg was found and applying a 100-safety factor, 
the acceptable daily intake of 0.2 mg/kg body weight was proposed. This is equiva-
lent to 12 mg glycyrrhizic acid/day for a 60-kg person [63]. Similarly, based on 
review of in vivo and clinical evidence, an acceptable daily intake has been proposed 
to be 0.015–0.229 mg glycyrrhizin/kg body weight [64]. The acceptable daily intake 
without a safety factor is equivalent to 120 mg glycyrrhizic acid. This dose could be 
considered safe if used short-term in a situation of high benefit versus risk.
4.5 Licorice pharmacokinetics
Glycyrrhiza glabra has shown weak inhibition of CYP3A4 and moderate inhibi-
tion of CYP2B6, 2C8, 2C9, and 2C19. Glycyrrhiza uralensis showed strong inhibition 
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of CYP2B6, moderate inhibition of CYP2C8, 2C9, and 2C19, and no inhibition of 
CYP3A4 and 2D6. Glycyrrhiza inflata strongly inhibited CYP2C enzymes and mod-
erately inhibited of CYP3A4, 1A2, 2B6, and 2D6. None of the three species inhibited 
CYP2E1 and 2A6. Glycyrrhizin content was highest in G. uralensis suggesting that 
glycyrrhizin is a weak inhibitor of the major enzymes CYP3A4 and 2D6 [65]. Weak 
inhibition of CYP3A4 and 2D6 by glycyrrhizin and G. glabra were also found in a 
different study [66].
4.6 Licorice safety summary
A safe daily dose for short-term use consists of licorice with less than 100 mg 
glycyrrhizin. For daily long-term use a dose of 12 mg glycyrrhizin has been pro-
posed. COVID-19 studies are using short-term doses of <100 mg glycyrrhizin per 
day. Caution should be taken when combining licorice with medications. Licorice 
inhibits several cytochrome P450 enzymes including CYP1A2, 2B6, 2C8, 2C9, and 
2C19. Only G. inflata inhibits CYP3A4 and 2D6.
5. Curcuma longa (turmeric) – Antiviral and anti-inflammatory
5.1 Turmeric in COVID-19
Turmeric has antiviral and anti-inflammatory effects that might benefit COVID-
19 patients [10, 13]. It has also been hypothesized that the antioxidant effects of 
turmeric benefit diabetic patients during COVID-19 infection [67]. However, some 
has expressed concerns that curcumin, the main active component of turmeric, 
might increase the expression of ACE2 and worsen COVID-19 infection as well 
as increase pro-inflammatory cytokines and worsen COVID-19 in patients with 
cytokine storm [26]. In the contrary, curcumin binds to viral S protein and the viral 
attachment sites of the ACE2 receptor protein to inhibit the entry of SARS-CoV2 
[18, 68]. In addition, curcumin has shown to reduce inflammatory cytokines in 
COVID-19 patients. In a clinical study with 40 COVID-19 patients, curcumin given 
as nano-curcumin at 160 mg/day for 14 days reduced the inflammatory cytokines 
IL-6 and IL-1β as well as clinical manifestations (fever, cough, dyspnea, headache, 
chest radiography, lymphocyte, white blood cells, and platelets count) in compari-
son to placebo-treated group. Both groups were taking atorvastatin, bromhexine, 
and betaferon concomitantly with 5–15% of them having diabetes, cardiovascular 
disease or renal disease. These results suggest the effectiveness and safety of 
curcumin in COVID-19 patients with underlying medical conditions [69].
5.2 Turmeric in diabetes
In clinical trials with type 2 diabetic patients, curcuminoids from 250 mg/day for 
9 months to 1 g/day for 3 months improved glycemic control, β-cell function, insu-
lin resistance, and reduced inflammatory cytokines with no major adverse effects. 
Minor side effects included diarrhea, constipation, vertigo, and itching. Some clini-
cal and preclinical studies also showed that curcumin improve biomarkers of liver 
and kidney damage [70]. In a clinical trial on 46 patients with diabetic nephropathy, 
1.5 g curcumin for 16 weeks improved 24-h urine analysis for albuminuria with no 
change in blood urea nitrogen, creatinine, fasting blood sugar, 2-h postprandial 
blood sugar, lipid profile, serum albumin, and hemoglobin A1C in comparison to 
placebo and baseline [71].
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5.3 Turmeric in heart disease
A recent meta-analysis found that turmeric or curcumin have no effect on 
diastolic blood pressure and minor effect on systolic blood pressure when taken for 
longer than 12 weeks [72]. A meta-analysis that included 7 randomized, placebo-
controlled clinical trials in patients with cardiovascular risk factors (i.e., non-
alcoholic fatty liver disease, metabolic syndrome, type 2 diabetes, prehypertension, 
and dyslipidemia) found turmeric powder at 2–2.4 g/day for 1–2 months, turmeric 
extract with 0.6–1.9 g curcuminoids/day for 2–6 months, or curcumin at 70–80 mg/
day for 2–3 months were effective in reducing serum LDL-cholesterol and triglyc-
erides levels. Adverse events reported were abdominal pain, nausea, dyspepsia, con-
stipation, and hot flushes. Hot flushes were also reported in the placebo group. In 3 
of the trials patients were kept on their medications during the study; however, only 
one trial disclosed the name of the concomitant drug treatment (metformin) [73].
5.4 Turmeric toxicity
Turmeric has GRAS status in the United States [74]. Through a toxicological 
assessment, the European Food Safety Authority (EFSA) has recommended curcumin 
daily intake be ≤3 mg/kg body weight per day (180 mg/day in 60 kg individuals) [75]. 
In 2–year oral feed studies, turmeric oil at 79–85% curcumin showed no biological 
significantly differences in hematology, clinical chemistry (liver and kidney function 
markers), and urinalysis parameters, but showed to potentially cause carcinogenicity 
in mice and rats especially in females at doses ≥100 mg/kg body weight in rats and 
300 mg/kg body weight in mice [76]. However, the EFSA concluded that curcumin 
is not carcinogenic and studies have demonstrated the benefits of curcumin as an 
adjunct treatment of cancer [77]. High daily dose of curcumin might cause hepa-
totoxicity. In rats, 25 and 100 mg/kg body weight for 90 days of curcumin induced 
liver injury through the generation of reactive oxygen species and pro-inflammatory 
cytokines as well as reduced antioxidant and detoxifying enzymes SOD and GST [78]. 
Similarly, 5% turmeric via diet for 90 days in female Wistar rats and 0.2% turmeric 
via diet in female Swiss mice was hepatotoxic. Human equivalent dose for these rodent 
studies ranged from 250 mg curcumin/day to 1 g–50 g turmeric/day [79, 80].
5.5 Turmeric pharmacokinetics
Turmeric constituents have shown to inhibit p-glycoprotein in vitro and in vivo 
models [81]. Inhibition of p-glycoprotein can lead to increased bioavailability of 
drugs [82]. Curcumin is primarily eliminated in the feces with little renal excre-
tion in a rat study [76]. In a pharmacokinetics study with healthy adults, turmeric 
reduced the bioavailability of the beta-blocker talinolol [83]. Curcumin was safe 
and effective when combined with glyburide in patients with type 2 diabetes. Better 
cholesterol and glycemia control without hypoglycemic side effects were observed. 
Curcumin increased AUC but did not change Cmax of glyburide [84]. In rats, 
curcumin increased the Cmax, AUC0-t and half-life of amlodipine – an antihyperten-
sive drug [85]. Amlodipine is metabolized by CYP3A4 in humans [86]. Curcumin 
inhibits several hepatic CYP enzymes including 3A4, 1A2, 2B6 (competitive type 
of inhibition), 2D6 and 2C9 (non-competitive inhibition) in human recombinant 
cytochrome P450s [87]. However, it is been suggested that these effects are not 
clinically significant due to poor bioavailability of curcumin. In fact, in a pharmaco-
kinetics study in healthy volunteers, 4 g curcuminoids +24 mg piperine to enhance 
bioavailability did not affect Cmax, AUC, clearance, or half-life of drugs metabolized 
by CYP3A, CYP2C9, and UGT, SULT conjugation enzymes [88].
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5.6 Turmeric safety summary
Turmeric is safe and effective at doses ≤250 mg curcumin/day. Higher doses 
are associated with hepatotoxicity and potentially carcinogenicity. Doses as low as 
70–250 mg curcuminoids/day has shown to be effective in metabolic disorders and 
COVID-19. Although turmeric inhibits cytochrome P450 enzymes, these effects 
seem to be clinically negligible. Caution when taken with drugs that are substrates 
of p-glycoprotein in order to avoid drug overdose. Although turmeric has hypo-
glycemic effects and might cause side effects such as fainting when combined with 
antidiabetic medications, this combination has shown to be safe in clinical trials.
6.  Nigella sativa (black seed) – Anti-inflammatory and respiratory 
support
6.1 Nigella sativa in COVID-19
N. sativa is a plant native to South East Asia with several pharmacological 
effects including bronchodilation, antitussive, and anti-inflammatory and used 
as treatments of respiratory conditions, diabetes, cardiovascular diseases, among 
others [89, 90]. For example, in a clinical trial with 90 obese women, 3 g/day of 
N. sativa oil for 8 weeks reduced serum levels of TNFα and hsCRP in comparison 
to placebo with no adverse events reported [91]. In patients with asthma, 1 g N. 
sativa oil per day for 4 weeks reduced several inflammatory markers and improved 
pulmonary function [92]. Preclinical studies have shown that constituents in the 
methanolic extract of N. sativa seeds are responsible for the bronchodilator effect 
[93]. Recently, N. sativa has been regarded as a potential therapy for COVID-19 
[13, 18, 94, 95]. For example, in a molecular docking-based study N. sativa inhibited 
SARS-CoV2 [94].
6.2 Nigella sativa in diabetes
Several clinical trials have been conducted to evaluate N. sativa in patients with 
type 2 diabetes [96]. For example, three controlled studies investigated the adjuvant 
use of 1–3 g/day N. sativa seeds powder or 2.5 ml/day N. sativa oil for 12 weeks in 
patients with type-2 diabetes. Significant and similar effects were observed with 
doses of 2 and 3 g/d on the reductions in fasting blood glucose, 2-hour postprandial 
glucose, HbA1C levels, and insulin resistance. Treatments were not associated 
with any adverse renal or hepatic functions throughout the study period. Patients 
were concomitantly taking oral hypoglycemic drugs (glibenclamide, metformin, 
rosiglitazone) but not insulin. Patients with coronary artery disease, valvular heart 
disease, heart failure, uncontrolled hypertension, renal failure and hepatic failure 
were excluded [97–99].
6.3 Nigella sativa in heart disease
In a meta-analysis including 11 randomized clinical trials with 860 hyperten-
sive or normotensive individuals, N. sativa seeds versus placebo and one versus 
standard treatment significantly reduced systolic blood pressure by −3.60 mmHg 
and diastolic blood pressure by −2.80 mmHg. [100]. A similar meta-analysis 
including 17 randomized clinical trials with 1185 individuals with hyperlipidemia, 
obesity, hypertension, type 2 diabetes, or others, found that N. sativa seed powder 
or oil 1–3 g/day for up to 3 months reduces total cholesterol, LDL-cholesterol, and 
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triglycerides [101]. No adverse events were reported by the subjects [102, 103]. One 
study in elderly with hypertension reported mild adverse events including dyspep-
sia in 6 subjects (15.7%), nausea in 3 subjects (7.8%), and constipation in 2 subjects 
(5.2%). No electrolyte abnormalities, liver and renal toxicities, or orthostatic 
hypotension were observed [104].
6.4 Nigella sativa toxicity
N. sativa has GRAS status in the United States [74]. A randomized, placebo-
controlled study with 40 healthy elderly investigated the safety profile after daily 
intake of 1 g N. sativa seed powder for 9 weeks. Results found no statistical changes 
in any of the biochemical markers of cardiac, liver, and kidney function [105]. In 
70 patients with chronic renal disease, 2.5 ml/day N. sativa oil for 12 weeks was 
safe and effective in improving clinical and biochemical parameters of kidney 
function without adverse events [106]. In a clinical trial with obese women, N. 
sativa oil (which is present in whole seeds and polar seed extracts), reduced body 
weight, VLDL cholesterol and triglycerides [107]. Traditional toxicity studies in 
rodents have been performed. In mice, hepatotoxicity was observed after 14-days 
of oral dosing at 6–21 g/kg body weight of N. sativa seeds water extract. No signs 
of hepatotoxicity were observed with methanolic and chloroform extracts. Body 
weight reductions were seen in methanolic extracts [108]. Similar findings were 
observed with the water extract in rats with increases in serum gamma-glutamyl 
transferase and alanine aminotransferase, but no changes in alkaline phosphatase 
and degeneration of hepatocytes [109]. In another rat study, 1 g/day for 6 weeks of 
whole N. sativa seeds were protective against hyperlipidemia to a similar extent as 
simvastatin without adverse effects to liver markers [110]. Human equivalent doses 
are 30–100 g N. sativa extracts per day for the mice study, and 10 g whole seeds per 
day for the rat study [80].
6.5 Nigella sativa pharmacokinetics
One of the main active constituents in N. sativa seeds and oil is thymoquinone. 
Thymoquinone has shown to bind to human α(1)-acid glycoprotein in the plasma 
[111] and inhibit CYP2C9 > 2D6 > 1A2 > 3A4 liver enzymes [112]. In hypertensive 
rats, N. sativa + alompidine showed greater reduction in blood pressure and heart 
rate than N. sativa alone, but no effect on alompidine pharmacokinetics (Cmax, 
AUC0-t, Kel, and terminal half-life) [113]. In another study in hypertensive rats, N. 
sativa + losartan showed greater reduction in blood pressure than N. sativa alone. N. 
sativa slightly reduced losartan Cmax and AUC0-t [114]. Alompidine is metabolized 
by CYP3A4 and losartan by CYP2C9 and 3A4 in humans. These data suggest that N. 
sativa has minimal effect on CYP3A4 but inhibits CYP2C9. In other words, N. sativa 
has antihypertensive effects on its own but potentiates the effect of drugs metabo-
lized by CYP2C9 which can cause further drop in blood pressure and lead to side 
effects such as fainting.
6.6 Nigella sativa safety summary
N. sativa whole seeds, oil or polar extracts (i.e., non-aqueous) at human doses 
up to 3 g/day for 12 weeks beneficially affect inflammatory and metabolic mark-
ers without adverse effects on heart, liver, or kidneys in healthy adults as well as 
in patients with heart disease and diabetes. N. sativa reduces blood glucose and 
blood pressure. Thus, caution when combining with hypoglycemic and antihy-
pertensive drugs to avoid side effects. N. sativa can increase the bioavailability of 
11
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drugs metabolized by CYP2C9 leading to higher risks of their side effects. Some 
diabetes and heart medications metabolized by CYP2C9 are losartan, fluvastatin, 
 glipizide [25].
7. Interactions summary
The combination of several dietary ingredients might be desirable when their 
main mechanisms of action and clinical effects differ. For example, combination of 
an anti-inflammatory, antiviral, immunostimulant, and bronchodilator herbs might 
be recommended. Safety combination of black seed and turmeric has been demon-
strated in a clinical study. N. sativa seed (1.5 g/d) and turmeric (2.4 g/d) in patients 
with metabolic syndrome for 4 weeks was safe and effective in reducing blood glu-
cose, cholesterol, and blood pressure despite both ingredients having hypoglycemic 
and antihypertensive effects alone [115]. Any effect of echinacea on blood glucose 
and blood pressure is insufficient to evaluate. Licorice can increase blood pres-
sure depending on the dose. Since turmeric and N. sativa have anti-hypertensive 
effects, the addition of licorice might be safe. All of the four dietary ingredients 
described here inhibit CYP2C9. All except N. sativa also inhibit CYP1A2. Turmeric 
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it. Thus, caution should be taken when combining these dietary ingredients with 
drugs metabolized by CYP3A4, 2C9, 1A2 and 2B6. As presented in Table 1, many 
drugs used in COVID-19, diabetes, and heart disease are metabolized by CYP3A4 
and 2C9. Caution should be taken with echinacea and turmeric because they induce 
or inhibit CYP3A4, respectively. Lastly, many drug examples presented in Table 2 
are excreted via urine. Turmeric and black seed are likely safe when combined with 
medications that are excreted by the kidneys. Caution when combining with licorice 
due to its potential to cause hyperkalemia. No sufficient evidence to evaluate 
echinacea’s effect on kidney function.
8. Conclusions
All the four dietary ingredients discussed herein are safe for use short-term 
as in a setting of treating a disease. However, some might not be safe when taken 
long-term. For example, no safety data was found for echinacea in heart disease 
and diabetes. Long-term use of low dose or short-term use of high dose licorice can 
cause reversible hypertension. Hepatotoxicity might occur with long-term use of 
turmeric >250 mg/day. Lastly, all of these four dietary ingredients are metabolized 
by cytochrome P450 enzymes to some extent. Mostly they inhibit CYP2C9, 1A2 and 
2B6. Caution with echinacea because it induces CYP3A4 and turmeric because it 
inhibits it.
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